Abstract
Introduction: Virotherapy is a promising new approach in cancer therapy. However, in prior work we have identified tumor cell lines originating from colon (HCT-15, KM12) or renal (ACHN) cancer exhibiting a primary resistance towards vaccine-derived virotherapeutics (vaccinia virus, VACV; measles vaccine virus, MeV); variants of both viruses are currently tested in clinical phase I/II trials (e.g., NCT01443260 & NCT00408590). To optimize the outcome of the virotherapeutic treatment we here investigated different schemes of combinatorial applications of recombinant oncolytic viruses of VACV and MeV origin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
